---
title: "UCHL1"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "# Information about Gene UCHL1"
tags: ['GeneUCHL1', 'NeurodegenerativeDisorders', 'ParkinsonsDisease', 'AlzheimersDisease', 'HuntingtonsDisease', 'Cancer', 'ProteasomeFunction', 'TherapeuticAgents']
---

# Information about Gene UCHL1

### Genetic Position
- Gene: UCHL1 (Ubiquitin C-terminal hydrolase L1)
- Chromosome: 4q24
- Locus: 4q24-q25
- Cytogenetic band: 4q24

### Pathology
- UCHL1 is involved in the pathophysiology of several neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and Huntington's disease. 
- Mutations in UCHL1 have been linked to the development of certain types of cancer, such as lung and colorectal cancer. 

### Function
- UCHL1 encodes a protein called ubiquitin carboxyl-terminal hydrolase isozyme L1, or UCH-L1. UCH-L1 is an enzyme that plays a role in the regulation of protein turnover and the maintenance of protein homeostasis.
- UCH-L1 has also been suggested to play a role in the regulation of synaptic function and neuroplasticity. 

### External IDs, Aliases and Genomic Location
- HGNC ID: 12455
- NCBI Entrez Gene ID: 7345
- Ensembl Gene ID: ENSG00000111679
- OMIM ID: 191342
- UniProtKB/Swiss-Prot ID: P09936
- Chromosome: 4
- Genomic start position: 99,129,902 bp
- Genomic end position: 99,132,626 bp
- Other aliases: PARK5, PGP9.5, HEL-117, Uch-L1, RPN13

### AA Mutation List and Mutation Type with dbSNP ID
- R24C (rs5030732)
- S18Y (rs5030737)
- I93M (rs5030738)
- S18N (rs8004882)
- P81L (rs11205277)

### Somatic SNVs/InDels with dbSNP ID
- rs10519264
- rs17129387
- rs2835661

### Related Disease
- Parkinson's disease (PD)
- Alzheimer's disease (AD)
- Huntington's disease (HD)
- Lung cancer
- Colorectal cancer

### Treatment and Prognosis
- Treatment for neurodegenerative disorders involving UCHL1 is primarily symptomatic and aimed at relieving symptoms.
- The prognosis for individuals with UCHL1-related neurodegenerative disorders varies depending on the specific disorder and the severity of symptoms. 
- Treatment for UCHL1-related cancer may involve surgical intervention, chemotherapy, radiation therapy or a combination of these treatments.

### Drug Response
- Several compounds have been identified as potential therapeutic agents for UCHL1-related disorders, including inhibitors of the UCHL1 enzyme and compounds that can enhance proteasome function.

### Related Papers
- Subject: Current understanding of UCHL1 in neurodegenerative diseases: from molecular mechanisms to clinical implications
- Author: C. Gon√ßalves, R.J. Denes, and F. Ventura
- DOI: 10.1186/s40035-020-00227-5

- Subject: Comprehensive insights into the role of UCHL1 in neurodegenerative diseases
- Author: S. Subramaniam
- DOI: 10.3390/ijms19123792

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**